Publications by authors named "Reyes de Torres Chacon"
Objective: Spain's so-called Stroke Belt is an area with high prevalence of vascular disease. We aimed to determine the prevalence of undetected obstructive sleep apnea-hypopnea syndrome (OSAHS) among patients with acute ischemic stroke (AIS) in southern Spain.
Methods: We conducted a cross-sectional study at the Virgen Macarena University Hospital Stroke Unit during 2018 to 2019.
Background And Aims: The benefits of the PCSK9 inhibitors, alirocumab and evolocumab, in lowering LDL-cholesterol and preventing major adverse cardiac events (MACE) have been demonstrated in pivotal clinical trials. However, few studies of routine clinical practice have been conducted to analyse and compare the efficacy and safety of the two drugs.
Methods: Retrospective observational study of patients treated with a PCSK9 inhibitor in five hospitals in Andalusia (southern Spain).
Objectives: The detection of cervical arterial dissection (CAD) has been rising in recent years owing to advanced imaging techniques. The aim of this study was to explore whether wide implementation of endovascular treatment for ischemic stroke has an impact on the diagnosis of CAD.
Methods: We included all patients with CAD diagnosed at two university hospitals in Seville, Spain from January 2015 to December 2017.
Article Synopsis
- Acenocoumarol is a blood thinner that shows different dosage needs among individuals due to genetic differences, specifically variants in CYP2C9 and VKORC1 genes.
- Researchers conducted a study on 78 Spanish stroke patients using a genome-wide association study to identify genetic variants linked to acenocoumarol dosage and complications like stroke recurrence and intracranial hemorrhage.
- They found 14 genetic variants related to dosage, with specific ones linked to stroke recurrence (6 variants) and intracranial hemorrhage (4 variants), emphasizing the importance of pharmacogenetic studies for improving anticoagulant therapy safety and effectiveness.
Objective/background: In 2006, the American Heart Association recommended that for preference carotid endarterectomy (CEA) or, alternatively, carotid angioplasty and stenting (CAS) for symptomatic carotid artery stenosis should ideally occur within 14 days of an ischaemic event. The aim was to determine the safety of CAS according to those recommendations in daily practice.
Methods: A retrospective analysis was performed of all consecutive patients (2000-16), with ipsilateral carotid symptoms who underwent CAS for extracranial carotid stenosis ≥70%, who were previously included in a prospective database.